Drug maker Shanghai Henlius traces its history to 1992, when four ambitious young entrepreneurs formed Fosun Group to seize ...

Novo Nordisk, the Danish pharma company behind Ozempic, made a very dumb decision a few years ago that will massively eat ...

Find out if Novo's GLP-1 patent expiring in Canada is a mistake or a calculated move. Did the firm lose exclusivity over a ...

Drugmakers want more clarity from the Trump administration on the potential pharmaceutical tariffs, which some companies warn ...

Generic Drugs Market Size to Reach USD 769.52 Billion by 2033 | Says Cervicorn ConsultingThe generic drugs market size is reaching an estimated value of USD 830.10 billion by 2034 rising from USD 327.

Introduction Over-the-counter (OTC) use of antibiotics contributes to the burgeoning rise in antimicrobial resistance (AMR). Drawing on qualitative research methods, this article explores the ...

Sandoz: This Swiss-based generic drugmaker ... including Novo Nordisk’s Victoza, Roche’s cancer drugs Rituxan (Truxima) and ...

Pharma companies involved in Vietnam are making more strategic moves to ease potential impacts in the face of US tariff ...

Sandoz Q1 2025 Growth and Tariff Impacts. Sandoz reported Q1 2025 net sales of $2.48 billion, with a 5% gain on a comparable growth basis. 1 Biosimilars were a major growth engine, generating $671 ...

Rutgers Health research identifies new trigger accelerating antibiotic resistance. Rutgers University. Journal Nature Communications DOI 10.1038/s41467-025-60302-6.

Medicare is negotiating the prices of 15 drugs, including Novo Nordisk's Ozempic.The government has until Nov. 30 to announce the agreed-upon Medicare prices. The lower prices would go into effect ...